// App-Quantinova.ai

141 : Nivolumab in Sorafenib‐Naive and ‐Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040

Researchers

Presenter

  • Bruno Sanaro

Principal Investigators

  • Thomas Yau

  • Chiun Hsu

  • Masatoshi Kudo

  • Tae-You Kim

  • Su-Pin Choo

  • Jorg Trojan

  • Theodore H. Welling

  • Timothy Meyer

  • Yoon-Koo Kang

  • Winnie Yeo

  • Akhil Chopra

  • Adyb Baakili

  • Christine dela Cruz

  • Huanyu Zhao

  • Jaclyn Neely

  • Todd S. Crocenzi

  • Anthony B. El-Khoueiry

Medical Centers

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Center for Applied Medical Research, Pamplona, Spain

  • University of Hong Kong, Hong Kong, China

  • Niigata University School of Medicine, Niigata, Japan

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • National Cancer Centre Singapore, Singapore, Singapore

  • Goethe University Hospital and Cancer Center, Frankfurt, Germany

  • University of Michigan School of Public Health, Ann Arbor, MI

  • The Royal Marsden Hospital, London, United Kingdom

  • Asan Medical Center, University of Ulsan, Seoul, Korea, Republic of (South)

  • University of Hong Kong, Hong Kong, China

  • Johns Hopkins Singapore International Medical Centre, Singapore, Singapore

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Providence Cancer Center, Portland, OR

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

Locations

  • Spain

  • China

  • Taiwan

  • Japan

  • Republic of South Korea

  • Singapore

  • Germany

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Nivolumab

  • Sorafenib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • I/II

Study Id's

  • NCT01658878

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved